Mylab, Hemex Health enter technology partnership for point of care diagnostics

Together, the companies will Fluorescence Immunoassay (FIA) and Electrophoresis-based diagnostic solutions. These tests are more sensitive than the normal rapid antigen tests and have fewer false negatives. The diagnostic solution will be jointly introduced in the international markets including the United States, Europe and Asia. This collaboration will bring together deep knowledge in molecular diagnostic technology, product ideation, and new technology development and deployment to augment testing capabilities for Covid-19 around the world.

Commenting on the partnership, Hasmukh Rawal, MD, Mylab Discovery Solutions, said, "We are thrilled to partner with Hemex, which has deep expertise in developing portable Point of Care diagnostics machines. Together with Mylab's accurate FIA test kits, we can make testing available anywhere – from a small village without electricity to an international airport. We believe this partnership will help India and the world prevent subsequent waves of Coronavirus".

Patti White, CEO & Co-founder, Hemex Health, said, "We are excited to announce the partnership with Mylab to provide new breakthrough testing for Covid-19 and other diseases in the future. This past year, Mylab has demonstrated outstanding ability to move quickly to solve big challenges posed by Covid-19. We share the same drive to make a difference for the people."

The Companies expect the first product from this technology partnership to be launched by November 2021. 

Read also: Mylab rolls out 10 lakh indigenous self test kits for COVID-19 priced at Rs 250 each